MedWatch

Italian hearing aid retailer disappoints with growth prognosis

Amplifon's long-term guidance has disappointed the market.

Photo: Jens Dresling

Hearing aid retailer Amplifon, which is based in Italy, has released new long-term sales guidance on Monday in connection with a capital market day at the company.

The report proved disappointing reading for the market, even though the company still expects significant growth in 2022 and 2023.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs